Nimble Therapeutics, Inc

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In the top alliance by deal value, PTC Therapeutics granted Novartis Pharmaceuticals exclusive global rights to its PTC518 Huntington’s disease program, which includes related molecules. Under the agr

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’